help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KANAZAWA, H.
Right arrow Articles by YOSHIKAWA, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KANAZAWA, H.
Right arrow Articles by YOSHIKAWA, J.

Am. J. Respir. Crit. Care Med., Volume 159, Number 1, January 1999, 165-168

Guinea Pig Airway Hyperresponsiveness Induced by Blockade of the Angiotensin II Type 1 Receptor
Role for Endogenous Nitric Oxide

HIROSHI KANAZAWA, KAZUTO HIRATA, and JUNICHI YOSHIKAWA

First Department of Internal Medicine, Osaka City University Medical School, Osaka, Japan

Losartan is the first angiotensin II type 1 (AT1) receptor antagonist to become available for the treatment of hypertension. However, recent reports have revealed several cases of losartan-induced bronchoconstriction. We investigated to determine the mechanism of losartan-induced bronchoconstriction, considering in particular the involvement of endogenous nitric oxide (NO). In this study, we examined the effects of losartan on airway obstruction and endogenous NO production using anesthetized guinea pigs and cultured airway epithelial cells. Five minutes after administration of angiotensin II (Ang II), the bronchoconstriction induced by acetylcholine was not changed. In contrast, Ang II in the presence of losartan caused a significant increase in the acetylcholine responsiveness. Pretreatment with L-N omega -nitroarginine-methylester (L-NAME) potentiated acetylcholine-induced bronchoconstriction 5 min after administration of Ang II, and L-arginine reversed this action of L-NAME on the acetylcholine responsiveness. Moreover, Ang II administration increased NO concentration in expired air (12.5 ± 1.5 ppb for saline, 40 ± 5 ppb for Ang II, p < 0.01), and losartan significantly inhibited Ang II-stimulated NO release (20 ± 3.5 ppb) from guinea pig airway. In cultured airway epithelial cells, Ang II also increased NO release (160 ± 25 nM), and the effect of this Ang II-induced NO release was significantly inhibited by pretreatment with losartan (25 ± 8 nM, p < 0.01). These findings suggest that losartan-induced bronchoconstriction may result from inhibition of endogenous NO release in the airway.




This article has been cited by other articles:


Home page
 ChestHome page
M. Cazzola, P. Noschese, G. D'Amato, and M. G. Matera
The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction
Chest, January 1, 2002; 121(1): 230 - 241.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society 		  ATS Quiz on Sleep Study Tracings